Authors' reply.

Dear Sir,

We were happy to receive the letter concerning our article titled “comparison of intracameral dexamethasone and intracameral triamcinolone acetonide (TA) injection at the end of phacoemulsification surgery.”[1] In this study, we aimed to compare the results of intracameral dexamethasone and intracameral TA injection in patients that underwent phacoemulsification surgery. This study demonstrated that intracameral dexamethasone and intracameral TA were similar effective in controlling postoperative inflammation after uncomplicated phacoemulsification surgery.

The author suggested that, a control group without intracameral injection who had prescribed only steroid drops immediately after surgery should have been considered in study design to evaluate the effects of intracameral TA and intracameral dexamethasone properly. Before this study, supporting articles[23] about the safety and efficiency of intracameral TA after cataract surgeries, encouraged us to apply intracameral injection of 2 mg/0.05 ml TA. However, in the period when we designed this study, approximately 3 years ago, the particulate structure of the TA and its tendency to increase the intraocular pressure in some patients and the studies articles[4] about the safety of intracameral dexamethasone after surgery in eyes with different types of glaucoma, forced us to substitute it with intracameral 0.4 mg/0.1 ml dexamethasone in our clinic. Because of this we chose to compare intracameral dexamethasone and intracameral TA in patients underwent uncomplicated phacoemulsification surgery in this study.

However, in this today’ situation with the recent developments in cataract surgical techniques and instruments, inflammation could be controlled in uncomplicated cases easily with only topical steroids. We also apply only topical steroids after the standard phacoemulsification surgery instead of intracameral steroid injection.